表３　症例Ｂの臨床経過と薬剤耐性変異の推移

	ダイレクトシーケンス法による薬剤耐性検査結果(高感度法の解析対象耐性変異)												
	逆転写酵素阻害剤耐性変異								PI耐性変異				
採血日	M41L	K65R	K70R	K103N	Y181C	M184V	T215Y	T215F	M46I	M46L	L90M	VL	ART
1997/3/24	-	-	-	-	-	-	-	-	-	-	-	1200000	d4T, 3TC, NFV
1998/1/12	M41L	WT	WT	WT	WT	M184V	T215Y	WT	-	-	-	28000	d4T, 3TC, NFV
1998/2/2	M41L	WT	WT	WT	WT	M184V	T215Y	WT	M46I	WT	L90M	45000	d4T, 3TC, NFV
1998/2/23	M41L	WT	WT	WT	WT	M184V	T215Y	WT	M46I	WT	WT	73100	d4T, 3TC, NFV
1998/5/11	-	-	-	-	-	-	-	-	WT	WT	L90M	589700	d4T, 3TC, NFV
1998/8/10	-	-	-	-	-	-	-	-	M46I	M46L	WT	86100	d4T, 3TC, NFV
1998/10/19	M41L	WT	WT	WT	WT	M184V	WT	WT	WT	M46L	L90M	61000	d4T, 3TC, NFV
1999/1/26	M41L	WT	WT	WT	WT	M184V	WT	WT	WT	M46L	L90M	98300	d4T, 3TC, NFV
1999/4/16	M41L	WT	WT	WT	WT	M184V	T215Y	WT	WT	M46L	L90M	104800	d4T, 3TC, NFV
1999/6/7	M41L	WT	WT	WT	WT	M184V	T215Y	WT	M46I	WT	L90M	157600	d4T, 3TC, NFV
1999/12/13	M41L	WT	WT	WT	WT	M184V	T215Y	WT	WT	M46L	L90M	167700	d4T, 3TC, NFV
2000/1/31	M41L	WT	WT	WT	-	M184V	T215Y	-	WT	M46L	L90M	10800	d4T, 3TC, NVP, NFV
2000/5/15	M41L	WT	WT	WT	Y181C	WT	T215Y	WT	M46V	M46V	L90M	51400	d4T, 3TC, NVP, NFV
2000/10/30	M41L	WT	WT	WT	Y181Y/C	M184M/V	T215Y	WT	WT	M46L	L90M	21000	-
2000/12/18	M41L	WT	WT	K103K/R	Y181Y/C	M184M/V	T215Y	WT	WT	M46L	L90M	57800	-
2001/2/7	M41L	WT	WT	WT	WT	WT	T215Y	WT	WT	WT	WT	52800	-
2001/5/28	WT	WT	K70R	WT	WT	WT	WT	WT	WT	WT	WT	600	ddI, d4T, NFV, LPV/r
2001/6/25	M41L	WT	WT	WT	-	-	-	-	WT	M46L	L90M	100	ddI, d4T, NFV, LPV/r
2002/4/22	M41L	WT	WT	WT	WT	WT	T215Y/S	WT	WT	M46L	L90M	1100	ddI, d4T, NFV, LPV/r
2002/10/28	M41L	WT	WT	WT	WT	WT	T215Y	WT	WT	M46L	L90M	16800	ddI, d4T, NFV, LPV/r
2002/11/18	M41L	K65K/R	WT	WT	WT	WT	T215Y	WT	WT	M46L	L90M	500	ddI, d4T, NFV, LPV/r
2003/5/12	M41L	WT	WT	WT	WT	WT	T215Y	WT	WT	M46L	L90M	34000	ddI, d4T, LPV/r
2003/6/9	M41L	WT	K70R	WT	WT	WT	T215Y/N/S	WT	-	-	-	45500	-
2003/7/28	M41L	WT	K70R	WT	WT	WT	T215Y/N/S	WT	WT	M46L	L90M	125300	-
2003/8/11	M41L	WT	K70R	WT	WT	WT	T215Y/N/S	WT	WT	WT	WT	97800	-
2003/9/8	M41L	WT	K70R	WT	WT	WT	T215Y/N/S	WT	WT	WT	WT	68900	-
2003/10/27	M41L	WT	K70R	WT	WT	WT	T215A	WT	-	-	-	3300	d4T, 3TC, ATV
2004/2/23	M41L	WT	WT	WT	WT	M184V	T215Y	WT	WT	M46L	L90M	8300	d4T, 3TC, ATV
2004/4/2	M41L	WT	WT	WT	WT	M184V	T215Y	WT	M46I	WT	L90M	46200	d4T, 3TC, ATV
2004/6/25	M41L	WT	WT	WT	WT	M184V	T215Y	WT	WT	M46L	L90M	30100	d4T, 3TC, ATV
2005/4/11	M41L	WT	WT	WT	WT	M184V	T215Y	WT	WT	M46L	L90M	14300	d4T, 3TC, ATV
2005/11/14	M41L	WT	WT	WT	WT	M184V	T215Y	WT	WT	M46L	L90M	5300	d4T, 3TC, ATV

表４　症例Ｃの臨床経過と薬剤耐性変異の推移

	ダイレクトシーケンス法による薬剤耐性検査結果(高感度法の解析対象耐性変異)												
	逆転写酵素阻害剤耐性変異								PI耐性変異				
採血日	M41L	K65R	K70R	K103N	Y181C	M184V	T215Y	T215F	M46I	M46L	L90M	VL	ART
1998/2/3	M41L	WT	WT	WT	WT	M184V	T215Y	WT	WT	WT	WT	61000	d4T, 3TC, AQV, NFV
1998/9/29	M41L	WT	WT	WT	WT	WT	T215Y	WT	M46I	WT	L90M	443500	d4T, 3TC, AQV, NFV
1999/2/2	M41L	WT	WT	WT	WT	M184V	T215Y	WT	M46I	WT	L90M	76200	d4T, 3TC, AQV, NFV
1997/7/14	M41L	WT	WT	WT	WT	WT	T215Y	WT	WT	WT	WT	13800	d4T, 3TC, AQV, NFV
1999/6/8	M41L	WT	WT	WT	WT	M184V	T215Y	WT	M46I	WT	L90M	39300	d4T, 3TC, AQV, NFV
2000/1/11	M41L	WT	WT	WT	WT	M184V	T215Y	WT	M46I	WT	L90M	8900	d4T, 3TC, AQV, NFV
2000/7/13	M41L	WT	WT	WT	WT	M184V	T215Y	WT	M46I	WT	L90M	35400	d4T, 3TC, AQV, NFV
2001/12/20	M41L	WT	WT	WT	WT	M184V	T215Y	WT	M46I	WT	L90M	17600	d4T, 3TC, AQV, NFV
2002/5/9	M41L	WT	WT	K103N	WT	M184V	T215Y	WT	M46I	WT	L90M	5000	ddI, d4T, EFV
2002/9/5	M41L	WT	WT	K103N	Y181C	WT	T215Y	WT	M46I	WT	L90M	19000	ddI, d4T, NVP
2003/5/22	M41L	WT	WT	K103N	Y181C	WT	T215Y	WT	M46I	WT	L90M	40100	ddI, d4T, NVP
2004/5/27	M41L	WT	WT	K103N	Y181C	WT	T215Y	WT	M46I	WT	L90M	36500	ddI, d4T, NVP
2004/11/25	WT	WT	WT	K103N	Y181C	WT	T215Y	WT	M46I	WT	L90M	34600	3TC, ABC, TDF
2005/2/15	WT	WT	WT	K103N	Y181C	WT	T215Y	WT	M46I	WT	L90M	71600	3TC, ABC, TDF
2006/1/24	WT	WT	WT	K103N	Y181C	WT	T215Y	WT	M46I	WT	L90M	70500	ddI, TDF, APV/r

表５　症例Ｄの臨床経過と薬剤耐性変異の推移

	ダイレクトシーケンス法による薬剤耐性検査結果(高感度法の解析対象耐性変異)												
	逆転写酵素阻害剤耐性変異								PI耐性変異				
採血日	M41L	K65R	K70R	K103N	Y181C	M184V	T215Y	T215F	M46I	M46L	L90M	VL	ART
1996/11/18	M41L	WT	WT	WT	WT	WT	T215Y	WT	WT	WT	WT	23000	AZT, RTV
1997/2/10	M41L	WT	WT	WT	WT	WT	T215Y	WT	WT	WT	WT	27000	-
1997/3/24	M41L	WT	WT	WT	WT	WT	T215Y	WT	WT	WT	WT	64090	AZT, 3TC, NFV
1997/11/10	M41L	WT	WT	WT	WT	M184V	T215Y	WT	WT	WT	WT	102000	-
1997/12/15	M41L	WT	WT	WT	WT	M184V	T215Y	WT	WT	WT	L/M	87000	SQV/r
1998/1/12	M41L	WT	WT	WT	WT	M184V	T215Y	WT	WT	WT	L90M	250000	SQV/r
1998/4/6	M41L	WT	WT	WT	WT	M184V	T215Y	WT	WT	WT	L90M	104500	ddI, d4T, 3TC
1998/5/25	M41L	WT	WT	WT	WT	M184V	T215Y	WT	WT	WT	L90M	186800	ddI, d4T, 3TC
1998/7/6	M41L	WT	WT	WT	WT	M184V	T215Y	WT	WT	WT	L90M	287700	ddI, d4T, 3TC
1998/7/27	M41L	WT	WT	WT	WT	M184V	T215Y	WT	WT	WT	L90M	149400	ddI, d4T, 3TC
1998/11/16	M41L	WT	WT	WT	WT	M184V	T215Y	WT	WT	WT	L90M	849500	ddI, d4T, 3TC
1999/1/26	M41L	WT	WT	WT	WT	M184V	T215Y	WT	WT	WT	L90M	165100	ddI, ddC, d4T
1999/2/22	M41L	WT	WT	WT	WT	M184V	T215Y	WT	WT	WT	L/M	100700	ddI, ddC, d4T
1999/3/29	M41L	WT	WT	WT	WT	M184V	T215Y	WT	WT	WT	L/M	136400	ddI, ddC, d4T
1999/4/12	M41L	WT	WT	WT	WT	M184V	T215Y	WT	WT	WT	WT	700	ddI, ddC, d4T
1999/5/10	M41L	WT	WT	K103N	WT	M184I	T215Y	WT	WT	WT	L90M	79300	ddI, d4T, 3TC
1999/5/17	M41L	WT	WT	K103N	WT	M184I	T215Y	WT	WT	WT	L90M	66300	ddI, d4T, 3TC
1999/5/31	M41L	WT	WT	K103N	WT	M184I	T215Y	WT	WT	WT	L90M	25600	ddI, d4T, 3TC
1999/7/12	M41L	WT	WT	K103N	WT	M184I	T215Y	WT	WT	WT	L90M	38300	ddI, d4T, 3TC
1999/8/16	M41L	WT	WT	K103N	WT	M184I	T215Y	WT	WT	WT	L90M	79500	ddI, d4T, 3TC
1999/10/4	M41L	WT	WT	K103N	Y181C	WT	T215Y	WT	WT	WT	L90M	42100	ddI, d4T, NFV
1999/11/1	M41L	WT	WT	K103N	Y181C	WT	T215Y	WT	WT	WT	L90M	21200	ddI, d4T, NFV
2000/1/18	M41L	WT	WT	K103N	Y181C	WT	T215Y	WT	WT	WT	L90M	11100	ddI, d4T, NFV
2000/2/21	M41L	WT	WT	K103NS	Y181C	WT	T215Y	WT	WT	WT	L90M	10700	ddI, d4T, 3TC, ABC, EFV
2000/4/24	-	-	-	-	-	-	-	-	WT	WT	L90M	13800	ddI, d4T, 3TC, ABC, EFV
2000/5/24	M41L	WT	WT	K103N	Y181C	WT	T215Y	WT	WT	WT	L90M	12500	ddI, d4T, 3TC, ABC, EFV
2000/6/26	M41L	WT	WT	K103N	Y181C	WT	T215Y	WT	WT	WT	L90M	9300	3TC, d4T, ABC, EFV
2000/9/25	WT	WT	WT	K103N	Y181C	WT	T215Y	WT	WT	WT	L90M	7900	3TC, d4T, ABC, EFV
2000/12/11	M41L	WT	WT	K103N	Y181C	WT	T215Y	WT	WT	WT	L90M	10000	d4T, ABC, EFV, NFV
2001/1/15	M41L	WT	WT	K103N	Y181C	WT	T215Y	WT	WT	WT	L90M	9100	d4T, ABC, EFV, NFV
2001/5/14	M41L	WT	WT	K103N	Y181C	WT	T215Y	WT	WT	WT	L90M	65900	d4T, ABC, EFV, NFV
2001/7/23	M41L	WT	WT	K103N	Y181C	WT	T215Y	WT	WT	WT	L90M	77200	ddI, d4T, ABC, EFV, NFV
2002/3/26	M41L	WT	WT	K103N	Y181C	WT	T215Y	WT	WT	WT	L90M	100	-
2003/3/24	M41L	WT	WT	K103N	Y181C	WT	T215Y	WT	WT	WT	L90M	8800	ddI, d4T, ABC, LPV/r
2003/4/14	M41L	WT	WT	K103N	Y181C	WT	T215Y	WT	WT	WT	L90M	22800	ddI, d4T, ABC, LPV/r
2003/7/28	M41L	WT	WT	K103N	Y181C	WT	T215Y	WT	WT	WT	L90M	10600	-
2004/5/28	M41L	WT	WT	K103N	Y181C	WT	T215Y	WT	WT	WT	L90M	-	-
2004/7/26	M41L	WT	WT	K103N	Y181C	WT	T215Y	WT	WT	WT	L90M	6500	ddI, ABC, ATV, LPV/r
2005/1/21	M41L	WT	WT	K103N	Y181C	WT	T215Y	WT	WT	WT	L90M	4200	ddI, ABC, ATV, LPV/r
2005/2/14	M41L	WT	WT	K103N	Y181C	WT	T215Y	WT	WT	WT	L90M	3300	ddI, ABC, ATV, LPV/r
2005/5/9	M41L	WT	WT	K103N	Y181C	WT	T215Y	WT	M/I	WT	L90M	9000	ddI, ABC, ATV, LPV/r

表６　症例Ｅの臨床経過と薬剤耐性変異の推移

	ダイレクトシーケンス法による薬剤耐性検査結果（高感度法の解析対象耐性変異）												
	逆転写酵素素材剤耐性変異								PI耐性変異				
採血日	M41L	K65R	K70R	K103N	Y181C	M184V	T215Y	T215F	M46I	M46L	L90M	VL	ART
1999/5/25	M41L	WT	WT	WT	WT	M184V	WT	WT	WT	WT	WT	3200	AZT, 3TC, IDV
1999/8/17	M41L	WT	WT	WT	WT	M184V	WT	WT	WT	WT	WT	2400	AZT, 3TC, IDV
1999/11/17	WT	WT	K70R	WT	WT	M184V	WT	WT	WT	M46L	WT	3100	AZT, 3TC, IDV
2000/4/4	M41L	WT	K70R	WT	WT	M184V	WT	WT	WT	M46L/M	WT	2500	AZT, 3TC, IDV
2000/6/28	M41L	WT	K70R	WT	WT	M184V	WT	WT	WT	M46L	WT	31600	AZT, 3TC, IDV
2000/9/20	M41L	WT	K70R	WT	WT	M184V	WT	WT	M46I/M	M46L/M	WT	2000	AZT, 3TC, IDV
2000/11/15	M41L	WT	K70R	WT	WT	M184V	WT	WT	M46I/M	WT	WT	2600	AZT, 3TC, IDV
2001/7/24	M41L	WT	K70R	WT	WT	M184V	WT	WT	M46I/M	WT	WT	10800	AZT, 3TC, IDV
2002/1/22	WT	WT	K70R	WT	WT	M184V	WT	WT	M46I/M	M46L/M	WT	2200	AZT, 3TC, IDV
2002/9/25	WT	WT	K70R	WT	WT	M184V	WT	WT	M46I/M	WT	WT	5200	AZT, 3TC, IDV
2002/11/12	WT	WT	K70R	WT	WT	M184V	WT	WT	M46I/M	WT	WT	2300	AZT, 3TC, IDV
2003/1/28	WT	WT	K70R	WT	WT	M184V	WT	WT	M46I	WT	WT	4800	AZT, 3TC, IDV
2003/4/8	WT	WT	K70R	WT	WT	M184V	WT	WT	M46I	WT	WT	12900	AZT, 3TC, IDV
2003/7/9	WT	WT	K70R	WT	WT	M184V	WT	WT	M46I	WT	WT	14800	AZT, 3TC, IDV
2003/10/7	WT	WT	K70R	WT	WT	M184V	WT	WT	M46I	WT	WT	21800	AZT, 3TC, IDV
2003/12/16	WT	WT	K70R	WT	WT	M184V	WT	WT	M46I	WT	WT	48900	AZT, 3TC, IDV
2004/3/16	WT	WT	K70R	WT	WT	M184V	WT	WT	M46I	WT	WT	16900	AZT, 3TC, IDV
2004/4/28	WT	WT	K70R	WT	WT	M184V	WT	WT	M46I	WT	WT	9900	AZT, 3TC, IDV
2004/6/23	WT	WT	K70R	WT	WT	M184V	WT	WT	M46I	WT	WT	60100	AZT, 3TC, IDV
2004/8/18	WT	WT	K70R	WT	WT	M184V	WT	WT	M46I	WT	WT	27700	AZT, 3TC, IDV
2004/10/5	WT	WT	K70R	WT	WT	M184V	WT	WT	M46I	WT	WT	10100	AZT, 3TC, IDV
2005/2/1	WT	WT	K70R	K103N	WT	M184V	WT	WT	M46I	WT	WT	33800	AZT, 3TC, IDV
2005/3/8	WT	WT	K70R	K103N	WT	M184V	WT	WT	M46I	WT	WT	15200	3TC, IDV, EFV
2005/4/12	WT	WT	K70R	K103N	WT	M184V	WT	WT	M46I	WT	WT	17700	3TC, IDV, EFV
2005/7/20	WT	WT	K70R	K103N	WT	M184V	WT	T215I	M46I	WT	WT	14400	3TC, IDV, EFV
2005/8/16	WT	WT	K70R	WT	WT	M184V	WT	T215I	M46I	WT	WT	4800	3TC, IDV, EFV
2005/10/18	WT	WT	K70R	WT	WT	M184V	WT	T215I	M46I	WT	WT	9400	3TC, IDV, EFV
2006/1/17	WT	WT	K70R	WT	WT	M184V	WT	T215I	M46I	WT	WT	13000	3TC, IDV, EFV
2006/3/22	WT	WT	K70R	WT	WT	M184V	WT	T215I	M46I	WT	WT	15500	3TC, IDV, EFV
2006/5/17	WT	WT	K70R	WT	WT	M184V	WT	T215I	M46I	WT	WT	10000	3TC, IDV, EFV

表７　症例Ｆの臨床経過と薬剤耐性変異の推移

	ダイレクトシーケンス法による薬剤耐性検査結果（高感度法の解析対象耐性変異）												
	逆転写酵素阻害剤耐性変異								PI耐性変異				
採血日	M41L	K65R	K70R	K103N	Y181C	M184V	T215Y	T215F	M46I	M46L	L90M	VL	ART
1998/10/27	M41L	WT	WT	WT	WT	M184V	WT	T215F	WT	WT	WT	33900	d4T, 3TC, TV
1999/2/9	M41L	WT	WT	WT	WT	M184V	WT	T215F	WT	WT	WT	44800	d4T, 3TC, TV
1999/6/10	M41L	WT	WT	WT	WT	M184V	WT	T215F	M46I	WT	WT	4000	d4T, 3TC, TV
1999/9/2	-	-	-	-	-	-	-	-	M46IM	WT	WT	358800	d4T, 3TC, TV
1999/12/13	-	-	-	-	-	M184MV	WT	T215F	M46I	WT	WT	900	ddI, d4T, EFV, SQV/r
2000/4/13	M41L	WT	WT	K103N	WT	M184MV	WT	T215F	M46I	WT	WT	9600	ddI, d4T, EFV, SQV/r
2000/7/13	M41L	WT	WT	K103N	WT	WT	WT	T215F	M46I	WT	WT	51500	ddI, d4T, EFV, SQV/r
2000/10/26	M41L	WT	WT	K103N	WT	WT	WT	T215F	M46I	WT	WT	18500	ddI, d4T, EFV, SQV/r
2001/5/14	M41L	WT	WT	K103N	WT	WT	WT	T215F	M46I	WT	WT	62000	ddI, d4T, EFV, SQV/r
2001/10/11	M41L	WT	WT	K103N	WT	WT	WT	T215F	M46I	WT	WT	23000	ddI, d4T, EFV, SQV/r
2002/1/30	M41L	WT	WT	K103N	WT	WT	WT	T215F	M46I	WT	WT	14700	ddI, d4T, EFV, SQV/r
2002/3/13	M41L	WT	WT	K103N	WT	WT	WT	T215F	M46I	WT	WT	41500	ddI, d4T, EFV, SQV/r
2002/7/23	M41L	WT	WT	K103N	WT	WT	WT	T215F	M46I	WT	WT	62000	ddI, d4T, EFV, SQV/r
2002/12/4	M41L	WT	WT	K103N	WT	WT	WT	T215F	M46I	WT	WT	50900	ddI, d4T, EFV, SQV/r
2003/5/28	M41L	WT	WT	K103N	WT	WT	WT	T215F	M46I	M46V	WT	97000	ddI, d4T, EFV, SQV/r
2003/9/30	M41L	WT	WT	K103N	WT	WT	WT	T215F	M46I	M46V	WT	117500	ddI, d4T, EFV, SQV/r
2004/1/28	M41L	WT	WT	K103N	WT	WT	WT	T215F	M46I	M46V	WT	219300	ddI, d4T, EFV, SQV/r
2004/5/19	M41L	WT	WT	K103N	WT	WT	WT	T215F	WT	WT	WT	23100	ddI, d4T, EFV, SQV/r
2004/6/29	M41L	WT	WT	K103N	WT	WT	WT	T215F	M46I	M46V	WT	40700	ddI, d4T, EFV, SQV/r
2004/11/2	M41L	WT	WT	K103N	WT	M184V	WT	T215F	M46I	WT	WT	28100	ddI, d4T, EFV, SQV/r
2005/1/12	M41L	WT	WT	K103N	WT	M184V	WT	T215F	M46I	WT	WT	26100	-
2005/3/9	M41L	WT	WT	K103N	WT	M184V	WT	T215F	M46I	WT	WT	21600	ddI, 3TC, LPV/r, TDF
2005/5/17	M41L	WT	WT	K103N	WT	M184V	WT	T215FV	M46I	WT	WT	19100	ddI, 3TC, LPV/r, TDF
2005/8/23	M41L	WT	WT	K103N	WT	M184V	WT	T215FV	M46I	WT	WT	34700	ddI, 3TC, LPV/r, TDF
2006/1/24	M41L	WT	WT	K103N	WT	M184V	WT	T215V	M46I	WT	WT	27400	ddI, 3TC, LPV/r, TDF

III. 研究成果の刊行に関する一覧表

別紙４

研究成果の刊行に関する一覧表レイアウト

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書　籍　名	出版社名	出版地	出版年	ページ
西澤雅子、杉浦亙	第7章　感染症治療の現状とメディカルニーズ第1節HIV	山脇　良平	各疾患領域の治療の現状とメディカルニーズDATA BOOK（第1刷）	技術情報協会	東京	2010	515-523

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Hirano A, Ikemura K, Takahashi M, Shibata M, Amioka K, Nomura T, Yokomaku Y, Sugiura W.	Lack of Correlation Between UGT1A1*6, *28 Genotypes, and Plasma Raltegravir Concentrations in Japanese HIV Type 1-Infected Patients.	AIDS Res Hum Retroviruses.	Epub ahead of print		2011
Revell AD, Wang D, Boyd MA, Emery S, Pozniak AL, De Wolf F, Harrigan R, Montaner JS, Lane C, Larder BA; RDI Study Group*(* RDI Study Group のメンバとして参加).	The development of an expert system to predict virological response to HIV therapy as part of an online treatment support tool.	AIDS	24;25(15)	1855-63	2011
Yotsumoto M, Shinozawa K, Yamamoto Y, Sugiura W, Miura T, Fukutake K.	Mutations to the probe of Cobas TaqMan HIV-1 ver. 1.0 assay causing undetectable viral load in a patient with acute HIV-1 infection.	J Infect Chemother.	17(6)	863-5	2011
Yoshida I, Sugiura W, Shibata J, Ren F, Yang Z, Tanaka H.	Change of positive selection pressure on HIV-1 envelope gene inferred by early and recent samples.	PLoS One.	6(4)	e18630	2011

Ibe S, Sugiura W.	Clinical significance of HIV reverse transcriptase inhibitor-resistant mutations.	Future Microbiol.	6(3)	295-315	2011
Shibata J, Sugiura W, Ode H, Iwatani Y, Sato H, Tsang H, Matsuda M, Hasegawa N, Ren F and Tanaka H.	Within-host co-evolution of Gag P453L and protease D30 N/N88D demonstrates virological advantage in a highly protease inhibitorexposed HIV-1 case	Antivir. Res.	90(1)	33-41	2011
Fujisaki S, Yokomaku Y, Shiino T, Koibuchi T, Hattori J, Ibe S, Iwatani Y, Iwamoto A, Shirasaka T, Hamaguchi M, Sugiura W.	Outbreak of hepatitis Bvirus genotype A and transmission of genetic drug resistance in cases coinfected with HIV-1 in Japan.	J Clin Microbiol.	49(3)	1017-24	2011
Ibe S., Sugiura W.	Clinical significance of HIV reverse transcriptase inhibitor-resistant mutations.	Future Microbiology.	in press		2010
Shibata J, Sugiura W, Ode H, Iwatani Y, Sato H, Tsang H, Matsuda M, Hasegawa N, Ren F, Tanaka H.	Within-host co-evolution of Gag P453L and protease D30N/N88D demonstrates virological advantage in a highly protease inhibitor-exposed HIV-1case.	Antiviral Res.	in press		2011
Fujisaki S, Yokomaku Y, Shiino T, Koibuchi T, Hattori J, Ibe S, Iwatani Y, Iwamoto A, Shirasaka T, Hamaguchi M, Sugiura W.	Outbreak of Infections by Hepatitis B Virus Genotype A and Transmission of Genetic Drug Resistance in Patients Coinfected with HIV-1 in Japan.	Clin Microbiol.	49(3)	1017-1024	2011

Hattori J, Shiino T, Gatanaga H, Yoshida S, Watanabe D, Minami R, Sadamasu K, Kondo M, Mori H, Ueda M, Tateyama M, Ueda A, Kato S, Ito T, Oie M, Takata N, Hayashida T, Nagashima M, Matsuda M, Ibe S, Ota Y, Sasaki S, Ishigatsubo Y, Tanabe Y, Koga I, Kojima Y, Yamamoto M, Fujita J, Yokomaku Y, Koike T, Shirasaka T, Oka S, Sugiura W.	Trends in transmitted drug-resistant HIV-1 and demographic characteristics of newly diagnosed patients: nationwide surveillance from 2003 to 2008 in Japan.	Antiviral Res.	88(1)	72-79	2011
Hirano A, Takahashi M, Kinoshita E, Shibata M, Nomura T, Yokomaku Y, Hamaguchi M, Sugiura W.	High performance liquid chromatography using UV detection for the simultaneous quantification of the new non-nucleoside reverse transcriptase inhibitor etravirine (TMC-125), and 4 protease inhibitors in human plasma.	Biol Pharm Bull.	33(8)	1426-1429	2010
Bandaranayake RM, Kolli M, King NM, Nalivaika EA, Heroux A, Kakizawa J, Sugiura W, Schiffer CA.	The effect of clade-specific sequence polymorphisms on HIV-1 protease activity and inhibitor resistance pathways.	J Virol.	84(19)	9995-10003	2010

Suzuki S, Urano E, Hashimoto C, Tsutsumi H, Nakahara T, Tanaka T, Nakanishi Y, Maddali K, Han Y, Hamatake M, Miyauchi K, Pommier Y, Beutler JA, Sugiura W, Fuji H, Hoshino T, Itotani K, Nomura W, Narumi T, Yamamoto N, Komano JA, Tamamura H.	Peptide HIV-1 integrase inhibitors from HIV-1 gene products.	J Med Chem.	53(14)	5356-5360	2010
Ibe S, Yokomaku Y, Shiino T, Tanaka R, Hattori J, Fujisaki S, Iwatani Y, Mamiya N, Utsumi M, Kato S, Hamaguchi M, Sugiura W.	HIV-2 CRF01_AB: first circulating recombinant form of HIV-2.	J Acquir Immune Defic Syndr.	54(3)	241-247	2010
Saeng-aroon S, Tsuchiya N, Auwanit W, Ayuthaya PI, Pathipvanich P, Sawanpanyalert P, Rojanawiwat A, Kannagi M, Ariyoshi K, Sugiura W.	Drug-resistant mutation patterns in CRF01_AE cases that failed d4T+3TC+nevirapine fixed-dosed, combination treatment: Follow-up study from the Lampang cohort.	Antiviral Res.	87(1)	22-29	2010
Matsuyama S, Shimizu A, Ode, H, Hata M, Sugiura W, Hoshino T.	Structural and Energetic Analysis on the Complexes of Clinically-isolated Subtype C HIV-1 Proteases and Approved Inhibitors by Molecular Dynamics Simulation.	The journal of physical chemistry. B	114	521-530	2010
Land S, Cunningham P, Zhou J, Frost K, Katzenstein D, Kantor R, Chen YM, Oka S, DeLong A, Sayer D, Smith J, Dax EM, Law M; TAQAS Laboratory Network	TREAT Asia Quality Assessment Scheme (TAQAS) to standardize the outcome of HIV genotypic resistance testing in a group of Asian laboratories.	J Virol Methods	159	185-93	2009

Hasegawa N, Sugiura W, Shibata J, Matsuda M, Ren F, Tanaka H.	Inferring within-patient HIV-1 evolutionary dynamics under anti-HIV therapy using serial virus samples with vSPA. BMC Bioinformatics.	BMC Bioinformatics	10	360	2009
Iwatani Y, Chan DS, Liu L, Yoshii H, Shibata J, Yamamoto N, Levin JG, Gronenborn AM, Sugiura W.	HIV-1 Vif-mediated ubiquitination/degradation of APOBEC3G involves four critical lysine residues in its C-terminal domain.	Proc Natl Acad Sci USA.	106	19539-19544	2009
杉浦 亙、服部純子.	HIV薬剤耐性変異の動向2003～2010年.	病原微生物検出情報.	32(10)	8-9	2011
杉浦 亙	HIVの指向性検査（トロピズムアッセイ）.	Confronting HIV.	40	1-3	2011
服部純子、杉浦 亙	薬剤耐性検査の現状と課題	化学療法の領域	27(3)	78-84	2011
伊部史朗、杉浦 亙	薬剤耐性HIVの現状と対策	日本臨牀	68(3)	476-479	2010
服部純子、杉浦 亙	我が国における薬剤耐性HIVの現状	感染・炎症・免疫	39(4)	361-363	2010
吉居廣朗、杉浦 亙	ラルテグラビルの耐性	医薬ジャーナル	46(8)	2054-2058	2010
杉浦 亙	5th International Workshop on HIV Transmission/ 18th International AIDS Conference	HIV感染症とAIDSの治療	1(2)	71-73	2010
杉浦 亙	HIV感染—最新の疫学・臨床・治療	内科	106(5)	781-787	2010
伊部史郎、横幕能行、杉浦亙	本邦におけるHIV-2の疫学動向と新たな組換え流行株CRF01_ABの同定	IASR	31(8)	232-233	2010
宮崎菜穂子、杉浦亙	わが国における抗HIV治療と多剤耐性症例の現状	IASR	31(8)	233-234	2010

KOKUYO セホ-50DM